Le Lézard
Classified in: Health
Subject: ACC

DSM - Repurchase of Shares (10 - 14 June 2019)


HEERLEN, Netherlands, June 18, 2019 /PRNewswire/ --

Royal DSM, a global science-based company in Nutrition, Health and Sustainable Living, has repurchased 147,395 of its own shares in the period from 10 June 2019 up to and including 14 June 2019 at an average price of ?106.02. This is in accordance with the repurchase announced on 14 March 2019, covering the intended reduction of issued capital as well as commitments under share-based compensation plans and for stock dividends. The consideration of this repurchase was ?15.6 million. 

     (Logo: https://mma.prnewswire.com/media/657851/DSM_Logo.jpg )

The total number of shares repurchased under this program to date is 2,353,355 shares for a total consideration of ?238.9 million.

For more detailed information see 'Daily transaction details Share Repurchase Program announced 14 March 2019'.

DSM - Bright Science. Brighter Living.tm 

Royal DSM is a global, purpose-led, science-based company active in Nutrition, Health and Sustainable Living. DSM's purpose is to create brighter lives for all. DSM addresses with its products and solutions some of the world's biggest challenges while simultaneously creating economic, environmental and societal value for all its stakeholders - customers, employees, shareholders, and society at large. DSM delivers innovative solutions for human nutrition, animal nutrition, personal care and aroma, medical devices, green products and applications, and new mobility and connectivity. DSM and its associated companies deliver annual net sales of about ?10 billion with approximately 23,000 employees. The company was founded in 1902 and is listed on Euronext Amsterdam. More information can be found at http://www.dsm.com.

Or find us on:

Facebook

Twitter

LinkedIn

YouTube

 

    PRN NLD


These press releases may also interest you

at 10:48
Health Canada is aware that Pfizer Canada is reporting that a shortage of its 0.3 mg format EpiPen auto-injector may lead to temporary supply constraints in the coming months. EpiPen Jr (0.15 mg) is not affected by this shortage. Health Canada...

at 10:35
High incidence of chronic diseases globally and the need for personalized medicine, has encouraged several technological advancements in the form of recombinant DNA that involves genetic combinations of species to treat diseases. The recombinant DNA...

at 10:32
Karo Pharma Aktiebolag ("Karo Pharma") today published its interim report for the period January - June 2019. On page 2 of the Swedish language version of the interim report, it was, slightly misleadingly, stated that a directed rights issue of...

at 10:30
141,000 jobs in BC are directly tied to BC's Forestry Industry. This industry generates $12.94 billion towards our province's GDP, and pulp and paper accounts for 16% of that total. There is, however, significant opportunity to enhance the value of...

at 10:05
Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty cannabis company focused on the research, development, and commercialization of novel cannabinoid-based products, is pleased to announce that it has received final approval to list...

at 10:00
JH Specialty is delighted to announce that our CEO, John Henry III, has been named the Distributor Entrepreneur of the Year by Advertising Specialty Institute's (ASI) Counselor Magazine. ASI is the promotional product industry's largest membership...



News published on 18 june 2019 at 03:00 and distributed by: